Attempted treatment of fulminant viral hepatitis with human fibroblast interferon

F. Milazzo, G. M. Vigevani, M. Almaviva, M. Galli, R. Esposito, A. Lazzarin, F. Caredda, P. Crocchiolo, M. Moroni, A. Cargnel, M. C. Perna, P. G. Fassio, G. Gavazzeni, A. Pugliese, P. A. Tovo

Research output: Contribution to journalArticlepeer-review


β-interferon was administered by intravenous infusion to 16 patients affected with fulminant hepatitis B virus infection in third or fourth-grade coma. Ten patients presented a superinfection or a co-infection due to the delta (δ)-agent. None had detectable interferon (IFN) activity before therapy was begun. Besides fever, no significant side-effects were observed during treatment. Both the IFN-treated group as well as the "historical" control group, made up of 70 cases of fulminant virus hepatitis, not treated with IFN and observed during a previous ten year-period, received supportive therapy; survival rates were similar in both groups. Furthermore, the presence or absence of the δ-agent did not appear to affect survival rates significantly.

Original languageEnglish
Pages (from-to)130-133
Number of pages4
Issue number3
Publication statusPublished - May 1985

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology


Dive into the research topics of 'Attempted treatment of fulminant viral hepatitis with human fibroblast interferon'. Together they form a unique fingerprint.

Cite this